A saponin with diverse biological activities
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Notoginsenoside Ft1

Item No. 24976

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(3β,12β,20R)-12,20-dihydroxydammar-24-en-3-yl O-β-D-xylopyranosyl-(1→2)-O-β-D-glucopyranosyl-(1→2)-β-D-glucopyranoside
CAS Number
155683-00-4
Molecular Formula
C47H80O17
Formula Weight
917.1
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 20 mg/mlDMF:PBS(pH 7.2)(1:1): 0.5 mg/mlDMSO: 15 mg/mlEthanol: 5 mg/ml
SMILES
O[C@H]1[C@@]2([H])[C@](CC[C@]2([H])[C@@](O)(C)CC/C=C(C)/C)(C)[C@]3(C)CC[C@]4([H])[C@@](CC[C@H](O[C@]5([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@@]6([H])[C@H](O[C@@]7([H])[C@H](O)[C@@H](O)[C@H](O)CO7)[C@@H](O)[C@H](O)[C@@H](CO)O6)C4(C)C)(C)[C@@]3([H])C1
InChi Code
InChI=1S/C47H80O17/c1-22(2)10-9-14-47(8,58)23-11-16-46(7)31(23)24(50)18-29-44(5)15-13-30(43(3,4)28(44)12-17-45(29,46)6)62-41-38(35(55)33(53)26(19-48)60-41)64-42-39(36(56)34(54)27(20-49)61-42)63-40-37(57)32(52)25(51)21-59-40/h10,23-42,48-58H,9,11-21H2,1-8H3/t23-,24+,25+,26+,27+,28-,29+,30-,31-,32-,33+,34+,35-,36-,37+,38+,39+,40-,41-,42-,44-,45+,46+,47+/m0/s1
InChi Key
LLXVPTXOKTYXHU-UGGLCNOCSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $29

    Add

    5 mg

    $92

    Add

    10 mg

    $113

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Notoginsenoside Ft1 is a saponin originally isolated from P. notoginseng with diverse biological activities.1,2,3,4,5 It induces proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs) via nuclear translocation of hypoxia-inducible factor-1α (HIF-1α) and activation of the PI3K/AKT and Raf/MEK/ERK signaling pathways in a manner dependent on mammalian target of rapamycin (mTOR).1 Notoginsenoside Ft1 (45 μM) induces cell cycle arrest at the S and G2/M phases and promotes apoptosis of SH-SY5Y cells.2 It increases cGMP levels and induces relaxation of isolated precontracted rat mesenteric arteries, effects that are reversed by the nitric oxide synthase inhibitor L-NAME (Item No. 80210) and ODQ (Item No. 81410), an inhibitor of soluble guanylyl cyclase.3 In vivo, notoginsenoside Ft1 (0.25, 2.5, and 25 mg/kg) promotes angiogenesis and decreases wound diameter in a mouse model of punched-hole ear injury.1 Notoginsenoside Ft1 (1.25 mg/kg) decreases tail bleeding time and increases thrombus weight in a rat tail bleeding assay.4 Topical administration of notoginsenoside Ft1 increases mRNA expression of the collagen expression, fibroblast proliferation, and scar formation genes COL1A1, COL3A1, TGF-β1, TGF-β3, and fibronectin, promotes neovascularization, reduces monocyte infiltration, and shortens wound closure time in a db/db mouse model of diabetic foot ulcers.5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Shen, K., Ji, L., Gong, C., et al. Notoginsenoside Ft1 promotes angiogenesis via HIF-1α mediated VEGF secretion and the regulation of PI3K/AKT and Raf/MEK/ERK signaling pathways. Biochem. Pharmacol. 84(6), 784-792 (2012).

    2. Gao, B., Shi, H.-L., Li, X., et al. p38 MAPK and ERK1/2 pathways are involved in the pro-apoptotic effect of notoginsenoside Ft1 on human neuroblastoma SH-SY5Y cells. Life Sci. 108(2), 63-70 (2014).

    3. Shen, K., Leung, S.W.S., Ji, L., et al. Notoginsenoside Ft1 activates both glucocorticoid and estrogen receptors to induce endothelium-dependent, nitric oxide-mediated relaxations in rat mesenteric arteries. Biochem. Pharmacol. 88(1), 66-74 (2014).

    4. Gao, B., Huang, L., Liu, H., et al. Platelet P2Y12 receptors are involved in the haemostatic effect of notoginsenoside Ft1, a saponin isolated from Panax notoginseng. Br. J. Pharmacol. 171(1), 214-223 (2014).

    5. Zhang, E., Gao, B., Yang, L., et al. Notoginsenoside Ft1 promotes fibroblast proliferation via PI3K/Akt/mTOR signaling pathway and benefits wound healing in genetically diabetic mice. J. Pharmacol. Exp. Ther. 356(2), 324-332 (2016).